The publication feed below is often incomplete and out of date; for an up to date summary of our publications please see Google Scholar or Pub Med
@article{Mondal:2022:10.1038/s41416-021-01516-5,
author = {Mondal, M and Conole, D and Nautiyal, J and Tate, E},
doi = {10.1038/s41416-021-01516-5},
journal = {British Journal of Cancer},
pages = {24--33},
title = {UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology},
url = {http://dx.doi.org/10.1038/s41416-021-01516-5},
volume = {126},
year = {2022}
}
TY - JOUR
AB - Breast cancer has the highest incidence and death rate among cancers in women worldwide. In particular, metastatic Estrogen Receptor negative (ER–) breast cancer and Triple-Negative Breast Cancer (TNBC) subtypes have very limited treatment options, with low survival rates. Ubiquitin carboxyl terminal hydrolase L1 (UCHL1), a ubiquitin C-terminal hydrolase belonging to the deubiquitinase (DUB) family of enzymes, is highly expressed in these cancer types, and several key reports have revealed emerging and important roles for UCHL1 in breast cancer. However, selective and potent small molecule UCHL1 inhibitors have been disclosed only very recently, alongside chemical biology approaches to detect regulated UHCL1 activity in cancer cells. These tools will enable novel insights into oncogenic mechanisms driven by UCHL1, and identification of substrate proteins deubiquitinated by UCHL1, with the ultimate goal of realizing the potential of UCHL1 as a drug target in breast cancer.
AU - Mondal,M
AU - Conole,D
AU - Nautiyal,J
AU - Tate,E
DO - 10.1038/s41416-021-01516-5
EP - 33
PY - 2022///
SN - 0007-0920
SP - 24
TI - UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology
T2 - British Journal of Cancer
UR - http://dx.doi.org/10.1038/s41416-021-01516-5
UR - http://hdl.handle.net/10044/1/90377
VL - 126
ER -